白细胞介素－2镇痛功能位点的研究

白细胞介－２（ＩＬ－２）是重要的免疫调节因子,近来发现还有中枢镇痛作用,用不同ＩＬ－２突变体测定其对大鼠痛阈的影响,发现完全丧失免疫刺激作用的２０Ｌｅｕ－ＩＬ－２（２０Ａｓｐ→Ｌｅｕ）仍能显著提高大鼠的痛阈,其作用强度与天然ＩＬ－２无显著差异,而另一突变体４５Ｖａｌ－ＩＬ－２（４５Ｔｙｒ→Ｖａｌ）虽保留免疫学活性却不能提高大鼠的痛阈;这些结果证明ＩＬ－２分子中具有镇痛作用与具有免疫作用与具有免疫作     

白细胞介素—2的中枢镇痛作用

本实验采用侧脑室给药,以钾离子透入法引起大鼠甩尾反应为指标,测定动物的痛阈,发现白细胞介素－２具有显著提高大鼠痛阈的作用,此作用能被抗ＩＬ－２单克隆抗体所阻断。纳洛酮能反转ＩＬ－２的镇痛作用,表明其作用机理与阿片受体有关。     

白细胞介素－2中枢镇痛作用途径的探讨

抗ＩＬ－２受体α亚基的单克隆抗体不能阻断ＩＬ－２的中枢镇痛作用,以及丧失与ＩＬ－２受体β亚基结合能力的ＩＬ－２突变体仍具有提高大鼠痛阈的能力,这表明ＩＬ－２的中枢镇痛作用并不是通过ＩＬ－２受体所介导,亦表示ＩＬ－２的免疫和镇痛作用是通过不同的受体途径实现的。加之内源性阿片肽与ＩＬ－２分子有着共同的抗原决定基和结构相似性,提示ＩＬ－２可以与阿片受体直接结合产生中枢镇痛效应。从放射免疫法测定的ＩＬ－２侧脑室注射后不同时间大鼠脑内不同核团的内源性阿片肽含量,推测ＩＬ－２的中枢镇痛作用可能还与弓状核、室旁核、蓝斑等核团的β－ＥＰ和ＬＥＫ有关。     

白细胞介素—2中枢镇痛作用途径的作用

抗ＩＬ－２受体α亚基的单克隆抗体不能阻断ＩＬ－２的中枢镇痛作用,以及丧失与ＩＬ－２受体β亚基结合能力的ＩＬ－２突变体仍具有提高大鼠阈的能力,这表明ＩＬ－２的中枢镇痛作用并不是通过ＩＬ－２受体所介导,亦表示ＩＬ－２的免疫和镇痛作用是通过不同的受体途径实现的。     

损毁和刺激垂体对大鼠痛阈的影响

采用局限性损毁和刺激垂体的方法,以行为测痛为指标,观察大鼠垂体在痛觉调节中的作用以及地塞米松（Ｄｅｘ）对其影响。实验结果显示,损毁垂体中间叶（ＩＬ）及邻近的前叶（ＡＬ）,大鼠痛阈明显低于手术前的痛阈（Ｐ＜０．０１）。电刺激垂体的上述同样部位,大鼠痛阈明显高于手术基础值及自身假刺激值（Ｐ＜０．００１）。经Ｄｅｘ处理的动物,电刺激垂体不再引起痛阈升高。结果表明,大鼠垂体ＩＬ及靠近ＡＬ与痛调节有关,这种     

白细胞介素2对大鼠垂体前叶细胞雌激素受体蛋白含量和基因表达的影响

采用原代无血清细胞培养技术结合免疫组织（细胞）化学和半定量反转录－ＰＣＲ方法,观察白细胞介素２（ＩＬ－２）对大鼠垂体前叶雌激素受体（ＥＲ）蛋白含量和基因表达的影响,以探讨ＩＬ－２和ＥＲ在大鼠重体前叶的相互关系。结果显示：在大鼠垂体前叶细胞有ＩＬ－２受体表达。在无血清培养条件下,ＩＬ－２能增加ＥＲα蛋白含量,促进ＥＲα基因表达,而对ＥＲβ的作用正好相反,ｒｈＩＬ－２（１０μｇ／Ｌ）作用４８ｈ后,ＥＲ     

L－谷氨酸分别兴奋大鼠内外侧缰核引起血压和痛阈变化的关系

本实验探讨分别兴奋缰核不同部位引起血压和痛阈变化的关系。实验分别在戊巴比妥钠和乌拉坦麻醉的大鼠上进行,采用玻璃微电极微量注射的方法,将Ｌ－谷氨酸（Ｌ－Ｇｌｕ）分别注入到大鼠内侧缰核（ＭＨｂ）和外侧缰核（ＬＨｂ）,分别观察痛阈和血压变化。结果显示：ＭＨｂ兴奋可明显提高痛阈和血压,痛阈提高５３％,血压由１３．８７±２．１４升高至１６．２１±２．４２ｋＰａ（Ｐ＜０．００１）。而ＬＨｂ兴奋引起痛阈降低３６％,血压由１４．８±２．０６降低到达１３．０９±１．８２ｋＰａ（Ｐ＜０．００１）。应用同一动物,分别兴奋内侧和外侧经核,同时观察痛阈和血压变化,所得结果和分组实验一致。结果表明兴奋缰核对痛阈和心血管活动的影响具有部位特异性,同时在现出两者之间的密切联系。     

白细胞介素2的中枢作用

白细胞介素２（ＩＬ－２）不仅是重要的免疫调节因子,而且具有重要的中枢调节作用。业已证实,脑内存在着ＩＬ－２和ＩＬ－２受体（ＩＬ－２Ｒ）,ＩＬ－２能明显地影响神经元和神经胶质细胞的生长,并能作用于下丘脑－垂体－肾上腺轴而影响内分泌,还能对电生理、行为等产生影响。本文简述了ＩＬ－２的中枢作用。     

吗啡对福尔马林引起大鼠海马内IL-2RβmRNA表达的影响

本实验采用原位杂交法观察足底注射福尔马林（Ｆｏｒ）痛敏对海马内白细胞介素２受体βｍＲＮＡ（ＩＬ－２ＲβｍＲＮＡ）生成的影响及其与吗啡、促肾上腺皮质激素（ＡＣＴＨ）的关系。结果表明：正常大鼠海马有ＩＬ－２ＲβｍＲＮＡ表达,集中分布于ＣＡ１－ＣＡ４区神经元、齿状回颗粒细胞。足底注射Ｆｏｒ后６ｈ双侧海马ＩＬ－２ＲβｍＲＮＡ表达均增加（Ｐ〈０．０５）,１２ｈ达高峰,２４ｈ仍高于正常。在６ｈ时,腹腔注射吗啡     

白介素-2诱发低血压动物的实验研究

白介素－２（ＩＬ－２）广泛用于治疗恶性肿瘤,由于大剂量可引起严重的低血压且机制不明,限制了其大剂量的使用。本研究用国产重组人白介素－２（ｒｈＩＬ－２）复制大鼠低血压模型并探讨其机制。２４只ｗｉｓｔａｒ大鼠随机分成３组（每组ｎ＝８）：正常对照组,ＩＬ－２实验组（ｒｈＩＬ－２）和氨基胍（ＡＧ）治疗组。结果显示：（１）ＩＬ－２可使大鼠提睾肌微动脉扩张及ＭＡＰ下降,肺、肾、肝组织Ｅｖａｎ′ｓＢｌｕｅ含量明显增加。（２）ＡＧ可使ｒｈＩＬ－２引起的低血压回升及微动脉缩小,肺组织Ｅｖａｎ′ｓＢｌｕｅ含量明显下降。提示：ｒｈＩＬ－２引起低血压,可能与ＩＬ－２诱导ＮＯ产生,使血管扩张及通透性增加有关。     

Inhibition of Spinal Interlukin-33/ST2 Signaling and Downstream ERK and JNK Pathways in Electroacupuncture Analgesia in Formalin Mice

Although acupuncture is widely used to manage pain, it remains highly controversial, largely due to the lack of a clear mechanism for its benefits. Here, we investigated the role of IL-33, a novel interleukin (IL)-1 family member, and its receptor ST2 in the analgesic effects of electroacupuncture (EA) on formalin-induced inflammatory pain. The results showed that 1) EA stimulation of ipsilateral Zusanli (ST 36) and Yanglingquan (GB 34) acupoints for 30 min remarkably suppressed the two phases of formalin-induced spontaneous pain; 2) subcutaneous or intrathecal administration of recombinant IL-33 (rIL-33) significantly inhibited the analgesic effect of EA, whereas the ST2 antibody potentiated EA analgesia in formalin mice; 3) EA treatment decreased the up-regulation of IL-33 and ST2 protein following formalin injection; and 4) the suppression of the formalin-induced expression of spinal phosphorylated ERK and JNK induced by EA treatment was significantly attenuated following subcutaneous rIL-33 delivery, and was further decreased by the ST2 antibody. These data suggest that EA alleviates formalin-induced inflammatory pain, at least partially, by inhibiting of spinal IL-33/ST2 signaling and the downstream ERK and JNK pathways.     

白细胞介素2新的功能位点及其中枢镇痛作用

白细胞介素２（ＩＬ－２）,不仅是重要的免疫调节因子,而且具有重要的中枢调节作用。本工作表明：（１）ＩＬ－２具有中枢镇痛作用;（２）ＩＬ－２除具有免疫调节作用功能位点外,还存在着另一新的与之相互独立的镇痛功能位点;（３）ＩＬ－２的中枢镇痛作用,主要是由ＩＬ－２第４５位Ｔｙｒ残基以及空间结构上邻近的４４、１１７位Ｐｈｅ等残基共同构成的镇痛功能位点与阿片受体直接结合所介导。本工作提示,细胞因子的多功能性,可能是其相互独立的功能位点作用于不同的受体或受体亚型所致。     

Interleukin-10 of Red Nucleus Plays Anti-Allodynia Effect in Neuropathic Pain Rats with Spared Nerve Injury

Our previous studies have shown that pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-α) and interleukin-1beta (IL-1β) in red nucleus (RN) are involved in the development of neuropathic pain and play facilitated roles on the mechanical allodynia induced by peripheral nerve injury. The current study was designed to evaluate the expression and effect of IL-10, an anti-inflammatory cytokine, in the RN of rats with spared nerve injury (SNI). Immunohistochemical staining results demonstrated when 3 weeks after SNI, the expression level of IL-10 in the contralateral RN of SNI rats was apparently higher than those of sham-operated and normal rats. To further study the effect of IL-10 in the development of neuropathic pain, different doses of IL-10 (1.0, 0.5 and 0.1 μg/μl) were microinjected respectively into the RN contralateral to the nerve injury side of SNI rats. Results demonstrated that higher doses of IL-10 (1.0 and 0.5 μg/μl) significantly attenuated the mechanical allodynia of neuropathic rats, while 0.1 μg/μl of IL-10 did not show any analgesic effect. These results suggest that IL-10 of RN participates in the development of neuropathic pain and plays inhibitory roles on the mechanical allodynia induced by SNI.     

Inhibitory effect of amygdalin on lipopolysaccharide-inducible TNF-alpha and IL-1beta mRNA expression and carrageenan-induced rat arthritis

Amygdalin is a cyanogenic glycoside plant compound found in the seeds of rosaceous stone fruits. We evaluated the antiinflammatory and analgesic activities of amygdalin, using an in vitro lipopolysaccharide (LPS)-induced cell line and a rat model with carrageenan-induced ankle arthritis. One mM amygdalin significantly inhibited the expression of TNF-alpha and IL-1beta mRNAs in LPS-treated RAW 264.7 cells. Amygdalin (0.005, 0.05, and 0.1 mg/kg) was intramuscularly injected immediately after the induction of carrageenan-induced arthritic pain in rats, and the anti-arthritic effect of amygdalin was assessed by measuring the weight distribution ratio of the bearing forces of both feet and the ankle circumference, and by analyzing the expression levels of three molecular markers of pain and inflammation (c-Fos, TNF-alpha, and IL-1beta) in the spinal cord. The hyperalgesia of the arthritic ankle was alleviated most significantly by the injection of 0.005 mg/kg amygdalin. At this dosage, the expressions of c-Fos, TNF-alpha, and IL-1beta in the spinal cord were significantly inhibited. However, at dosage greater than 0.005 mg/kg, the painrelieving effect of amygdalin was not observed. Thus, amygdalin treatment effectively alleviated responses to LPStreatment in RAW 264.7 cells and carrageenan-induced arthritis in rats, and may serve as an analgesic for relieving inflammatory pain.     

Bovine endozepine potentiates morphine analgesia in mice

This paper describes the influence of bovine endozepine (BEP) on the analgesic effect of morphine. The intraventricular administration of BEP between doses of 2-4 nmole in mice resulted in the potentiation of the morphine-analgesic effect. The basic pain threshold did not change when BEP was given alone, thus indicating that BEP is unable to elicit analgesic effect alone. Intravenous injection of BEP in the dose range of 5-7.5 mg/kg also potentiated the analgesic effect of morphine. These observations suggest that endozepine can act as a regulator of pain.     

Intrathecal Infusion of Hydrogen-Rich Normal Saline Attenuates Neuropathic Pain via Inhibition of Activation of Spinal Astrocytes and Microglia in Rats

Background

Reactive oxygen and nitrogen species are key molecules that mediate neuropathic pain. Although hydrogen is an established antioxidant, its effect on chronic pain has not been characterized. This study was to investigate the efficacy and mechanisms of hydrogen-rich normal saline induced analgesia.

Methodology/Principal findings

In a rat model of neuropathic pain induced by L5 spinal nerve ligation (L5 SNL), intrathecal injection of hydrogen-rich normal saline relieved L5 SNL-induced mechanical allodynia and thermal hyperalgesia. Importantly, repeated administration of hydrogen-rich normal saline did not lead to tolerance. Preemptive treatment with hydrogen-rich normal saline prevented development of neuropathic pain behavior. Immunofluorochrome analysis revealed that hydrogen-rich normal saline treatment significantly attenuated L5 SNL-induced increase of 8-hydroxyguanosine immunoreactive cells in the ipsilateral spinal dorsal horn. Western blot analysis of SDS/PAGE-fractionated tyrosine-nitrated proteins showed that L5 SNL led to increased expression of tyrosine-nitrated Mn-containing superoxide dismutase (MnSOD) in the spinal cord, and hydrogen-rich normal saline administration reversed the tyrosine-nitrated MnSOD overexpression. We also showed that the analgesic effect of hydrogen-rich normal saline was associated with decreased activation of astrocytes and microglia, attenuated expression of interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) in the spinal cord.

Conclusion/Significance

Intrathecal injection of hydrogen-rich normal saline produced analgesic effect in neuropathic rat. Hydrogen-rich normal saline-induced analgesia in neuropathic rats is mediated by reducing the activation of spinal astrocytes and microglia, which is induced by overproduction of hydroxyl and peroxynitrite.     

Collecting And Measuring Wound Exudate Biochemical Mediators In Surgical Wounds

We describe a methodology by which we are able to collect and measure biochemical inflammatory and nociceptive mediators at the surgical wound site. Collecting site-specific biochemical markers is important to understand the relationship between levels in serum and surgical wound, determine any associations between mediator release, pain, analgesic use and other outcomes of interest, and evaluate the effect of systemic and peripheral drug administration on surgical wound biochemistry. This methodology has been applied to healthy women undergoing elective cesarean delivery with spinal anesthesia. We have measured wound exudate and serum mediators at the same time intervals as patient''s pain scores and analgesics consumption for up to 48 hours post-cesarean delivery. Using this methodology we have been able to detect various biochemical mediators including nerve growth factor (NGF), prostaglandin E2 (PG-E2) substance P, IL-1β, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17, TNFα, INFγ, G-CSF, GM-CSF, MCP-1 and MIP-1β. Studies applying this human surgical wound bioassay have found no correlations between wound and serum cytokine concentrations or their time-release profile (J Pain. 2008; 9(7):650-7).¹ We also documented the utility of the technique to identify drug-mediated changes in wound cytokine content (Anesth Analg 2010; 111:1452-9).²     

The Central Analgesic Mechanism of YM-58483 in Attenuating Neuropathic Pain in Rats

Calcium channel antagonists are commonly used to treat neuropathic pain. Their analgesic effects rely on inhibiting long-term potentiation, and neurotransmitters release in the spinal cord. Store-operated Ca²⁺channels (SOCCs) are highly Ca²⁺-selective cation channels broadly expressed in non-excitable cells and some excitable cells. Recent studies have shown that the potent inhibitor of SOCCs, YM-58483, has analgesic effects on neuropathic pain, but its mechanism is unclear. This experiment performed on spinal nerve ligation (SNL)-induced neuropathic pain model in rats tries to explore the mechanism, whereby YM-58483 attenuates neuropathic pain. The left L5 was ligated to produce the SNL neuropathic pain model in male Sprague–Dawley rats. The withdrawal threshold of rats was measured by the up–down method and Hargreaves’ method before and after intrathecal administration of YM-58483 and vehicle. The SOCCs in the spinal dorsal horn were located by immunofluorescence. The expression of phosphorylated ERK and phosphorylated CREB, CD11b, and GFAP proteins in spinal level was tested by Western blot, while the release of proinflammatory cytokines (IL-1β, TNF-α, PGE2) was measured by enzyme-linked immunosorbent assay (ELISA). Intrathecal YM-58483 at the concentration of 300 μM (1.5 nmol) and 1000 μM (10 nmol) produced a significant central analgesic effect on the SNL rats, compared with control + vehicle (n = 7, P < 0.001). However, both could not prevent the development of neuropathic pain, compared with normal + saline (P < 0.001). Immunofluorescent staining revealed that Orai1 and STIM1 (the two key components of SOCCs) were located in the spinal dorsal horn neurons. Western blot showed that YM-58483 could decrease the levels of P-ERK and P-CREB (n = 10, #P < 0.05), without affecting the expression of CD11b and GFAP (n = 10, #P > 0.05). YM-58483 also inhibited the release of spinal cord IL-1β, TNF-α, and PGE2, compared with control + vehicle (n = 5, #P < 0.001). The analgesic mechanism of YM-58483 may be via inhibiting central ERK/CREB signaling in the neurons and decreasing central IL-1β, TNF-α, and PGE2 release to reduce neuronal excitability in the spinal dorsal horn of the SNL rats.     

Mechanisms of effect of adrenocorticotropic hormone on the rat pain sensitivity

The mechanisms of effect of adrenocortricotropic hormone on pain sensitivity were studied in anaesthetized Sprague-Dawley male rats. Systemic ACTH administration increased the pain thresholds (from 3 min up to the 30 min after injection) in rats with normal production of hormones. The initial stage of ACTH analgesic effect was fully eliminated by blockade of opiate receptors, ACTH-induced reaction was observed only from 15 up to 30 min after injection. In rats with deficiency of glucocorticoids production, the duration of ACTH-induced analgesic effect decreased to 15 min. The analgesic effect was completely prevented by combination of blockade of glucocorticoids production and blockade of opiate receptors. Thus the ACTH-induced analgesic effect is provided at least by two mechanisms: 1) appearing during the first minutes after injection (from 3 min up to 15 min) and mediated by opiate receptors rather than glucocorticoids, and 2) appearing from 15 min up to 30 min after injection and mediated by glucocorticoids but not opiate receptors.